{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:00:35Z","timestamp":1792224035880,"version":"4.4.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Precision medicine approaches such as ex vivo drug sensitivity screening (DSS) are appealing to inform rational drug selection in myelodysplastic syndromes (MDSs) and acute myeloid leukemia, given their marked biologic heterogeneity. We evaluated a novel, fully automated ex vivo DSS platform that uses high-throughput flow cytometry in 54 patients with newly diagnosed or treatment-refractory myeloid neoplasms to evaluate sensitivity (blast cytotoxicity and differentiation) to 74 US Food and Drug Administration\u2013approved or investigational drugs and 36 drug combinations. After piloting the platform in 33 patients, we conducted a prospective feasibility study enrolling 21 patients refractory to hypomethylating agents (HMAs) to determine whether this assay could be performed within a clinically actionable time frame and could accurately predict clinical responses in vivo. When assayed for cytotoxicity, ex vivo drug sensitivity patterns were heterogeneous, but they defined distinct patient clusters with differential sensitivity to HMAs, anthracyclines, histone deacetylase inhibitors, and kinase inhibitors (P &amp;lt; .001 among clusters) and demonstrated synergy between HMAs and venetoclax (P &amp;lt; .01 for combinations vs single agents). In our feasibility study, ex vivo DSS results were available at a median of 15 days after bone marrow biopsy, and they informed personalized therapy, which frequently included venetoclax combinations, kinase inhibitors, differentiative agents, and androgens. In 21 patients with available ex vivo and in vivo clinical response data, the DSS platform had a positive predictive value of 0.92, negative predictive value of 0.82, and overall accuracy of 0.85. These data demonstrate the utility of this approach for identifying potentially useful and often novel therapeutic drugs for patients with myeloid neoplasms refractory to standard therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001934","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T14:39:34Z","timestamp":1592836774000},"page":"2768-2778","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Ex vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms"],"prefix":"10.1182","volume":"4","author":[{"given":"Michael A.","family":"Spinner","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Aleshin","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne T.","family":"Santaguida","sequence":"first","affiliation":[{"name":"Notable Labs, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Schaffert","sequence":"first","affiliation":[{"name":"Notable Labs, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Zehnder","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Scott","family":"Patterson","sequence":"first","affiliation":[{"name":"Notable Labs, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3429-4145","authenticated-orcid":false,"given":"Christos","family":"Gekas","sequence":"first","affiliation":[{"name":"Notable Labs, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Heiser","sequence":"first","affiliation":[{"name":"Notable Labs, Foster City, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Greenberg","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Stanford University Medical Center, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"issue":"20","key":"2020062311293016400_B1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2020062311293016400_B2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020062311293016400_B3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"7367","key":"2020062311293016400_B4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2020062311293016400_B5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"26","key":"2020062311293016400_B6","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2020062311293016400_B7","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2020062311293016400_B8","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"2020062311293016400_B9","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020062311293016400_B10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"2020062311293016400_B11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"8","key":"2020062311293016400_B12","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"15","key":"2020062311293016400_B13","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020062311293016400_B14","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020062311293016400_B15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1182\/blood-2013-08-496935","article-title":"How we treat higher-risk myelodysplastic syndromes","volume":"123","author":"Sekeres","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2020062311293016400_B16","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/bloodadvances.2018015834","article-title":"Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy","volume":"2","author":"Aleshin","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2020062311293016400_B17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"21","key":"2020062311293016400_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.483.483","article-title":"Personalized approach to treatment of acute myeloid leukemia using a high-throughput chemosensitivity assay","volume":"122","author":"Yeung","year":"2013","journal-title":"Blood."},{"issue":"22","key":"2020062311293016400_B19","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1675.1675","article-title":"Ex-vivo drug response profiling for precision medicine approaches in acute myeloid leukemia with the Open Microwell Microfluidic Platform","volume":"128","author":"Rocchi","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2020062311293016400_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.5206.5206","article-title":"Ex vivo high-throughput flow cytometry screening identifies subsets of responders to differentiation agents in individual AML patient samples","volume":"128","author":"Prashad","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2020062311293016400_B21","article-title":"A genomic signature predicting venetoclax treatment response in AML identified by protein network mapping and validated by ex vivo drug sensitivity testing: a Beat AML Project study","volume":"128","author":"Drusbosky","year":"2016","journal-title":"Blood."},{"issue":"11","key":"2020062311293016400_B22","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020062311293016400_B23","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","article-title":"Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study","volume":"4","author":"Snijder","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"2020062311293016400_B24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"issue":"301","key":"2020062311293016400_B25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/01621459.1963.10500845","article-title":"Hierarchical grouping to optimize an objective function","volume":"58","author":"Ward","year":"1963","journal-title":"J Am Stat Assoc"},{"key":"2020062311293016400_B26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10208-009-9045-5","article-title":"Exact matrix completion via convex optimization","volume":"9","author":"Cand\u00e8s","year":"2009","journal-title":"Found Comput Math"},{"key":"2020062311293016400_B27","first-page":"83","article-title":"CVXPY: A Python-embedded modeling language for convex optimization","volume":"17","author":"Diamond","year":"2016","journal-title":"J Mach Learn Res"},{"issue":"2","key":"2020062311293016400_B28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2307\/3001913","article-title":"Comparing individual means in the analysis of variance","volume":"5","author":"Tukey","year":"1949","journal-title":"Biometrics"},{"issue":"2","key":"2020062311293016400_B29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2020062311293016400_B30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/115487","article-title":"Measures of location and scale for velocities in clusters of galaxies - A robust approach","volume":"100","author":"Beers","year":"1990","journal-title":"Astron J"},{"issue":"1","key":"2020062311293016400_B31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"1","key":"2020062311293016400_B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/aos\/1176344552","article-title":"Bootstrap methods: another look at the Jackknife","volume":"7","author":"Efron","year":"1979","journal-title":"Ann Stat"},{"issue":"12","key":"2020062311293016400_B33","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"issue":"36","key":"2020062311293016400_B34","doi-asserted-by":"crossref","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","article-title":"Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies","volume":"114","author":"Kurtz","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020062311293016400_B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.11.008","article-title":"Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study","volume":"64","author":"Swords","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"2020062311293016400_B36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","article-title":"Drug-perturbation-based stratification of blood cancer","volume":"128","author":"Dietrich","year":"2018","journal-title":"J Clin Invest"},{"issue":"34","key":"2020062311293016400_B37","doi-asserted-by":"crossref","first-page":"56338","DOI":"10.18632\/oncotarget.17630","article-title":"Identification of precision treatment strategies for relapsed\/refractory multiple myeloma by functional drug sensitivity testing","volume":"8","author":"Majumder","year":"2017","journal-title":"Oncotarget"},{"issue":"7728","key":"2020062311293016400_B38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"12","key":"2020062311293016400_B39","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"issue":"1","key":"2020062311293016400_B40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","author":"Bogenberger","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020062311293016400_B41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2020062311293016400_B42","doi-asserted-by":"crossref","unstructured":"Wei\n              AH\n            , GarciaJS, BorateU, et al A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-na\u00efve patients with higher-risk myelodysplastic syndrome [abstract]. Blood. 2019;134(suppl 1). Abstract 568.","DOI":"10.1182\/blood-2019-124437"},{"key":"2020062311293016400_B43","doi-asserted-by":"crossref","unstructured":"Zeidan\n              AM\n            , PollyeaDA, GarciaJS, et al A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome [abstract]. Blood. 2019;134(suppl 1). Abstract 565.","DOI":"10.1182\/blood-2019-124994"},{"issue":"1","key":"2020062311293016400_B44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/10428190701757827","article-title":"Vitamin D compounds and myelodysplastic syndrome","volume":"49","author":"Okamoto","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020062311293016400_B45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.leukres.2009.10.004","article-title":"Different susceptibilities to 1,25-dihydroxyvitamin D3-induced differentiation of AML cells carrying various mutations","volume":"34","author":"Gocek","year":"2010","journal-title":"Leuk Res"},{"issue":"1","key":"2020062311293016400_B46","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3324\/haematol.13378","article-title":"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B","volume":"94","author":"Schlenk","year":"2009","journal-title":"Haematologica"},{"issue":"5","key":"2020062311293016400_B47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11899-017-0412-z","article-title":"Computational modeling and treatment identification in the myelodysplastic syndromes","volume":"12","author":"Drusbosky","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"2020062311293016400_B48","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/bloodadvances.2018028316","article-title":"A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients","volume":"3","author":"Drusbosky","year":"2019","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2768\/1745752\/advancesadv2020001934.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/12\/2768\/1745752\/advancesadv2020001934.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T15:30:15Z","timestamp":1592926215000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/12\/2768\/461056\/Ex-vivo-drug-screening-defines-novel-drug"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001934","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]}}}